Danaher launches collaboration with cincinnati children's hospital medical center aiming to improve patient safety in early drug development

Danaher beacon for preclinical drug safety seeks to address major cause of failure in clinical trials program will leverage automated liver organoid technology for drug toxicity screening aims to expand genetic diversity of screening, accelerate therapy development, and help ensure patient safety washington , feb. 5, 2024 /prnewswire/ -- danaher corporation (nyse: dhr), a global science and technology innovator, today launched a strategic collaboration with cincinnati children's hospital medical center, with the goal of improving patient safety by addressing a leading cause of failure in clinical trials. as part of the danaher beacons program, the multi-year collaboration aims to improve liver organoid technology as a drug toxicity screening solution for safeguarding patients, which could accelerate development of new therapies and potentially save billions of dollars in wasted research and development productivity each year.
DHR Ratings Summary
DHR Quant Ranking